Ligand reports Q3 adjusted EPS $3.09, consensus $1.89

Reports Q3 revenue $115.5M, consensus $58.05M. “We are pleased to report an increase in our financial guidance for the second time this year, as a result of the continued strength and momentum of our growing commercial royalty portfolio,” said Todd Davis, CEO of Ligand (LGND). “This was a pivotal quarter for Ligand. We successfully completed a convertible debt financing, providing us with additional resources to pursue strategic investment opportunities that support our growth initiatives. Additionally, I’m proud of our investment team’s ability to create superior returns through transactions such as the strategic merger of Pelthos with Channel Therapeutics, which has driven substantial value creation for our shareholders.”